Archive: August 2017

The Role of Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Joseph R. Mikhael, MD, MEd

  H&O  What are the clinical characteristics of multiple myeloma? JM  Multiple myeloma has historically been defined by 4 clinical characteristics: elevated calcium, renal deficiency, anemia, […]

The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade

Khinh Ranh Voong, MD, MPH, Jarushka Naidoo, MBBCh, and David S. Ettinger, MD, FACP, FCCP

  Abstract: Immune checkpoint blockade (ICB), which harnesses the body’s immune system to recognize and kill cancer cells, has transformed the management landscape for patients with […]

New Treatments for Stage I Testicular Cancer

Lucia Nappi, MD, PhD, Craig R. Nichols, MD, and Christian K. Kollmannsberger, MD

  Abstract  Clinical stage I represents the most frequent presentation of both seminoma and nonseminoma testicular cancer. Despite a survival rate of close to 100%, the […]

Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges

Mary-Elizabeth Percival, MD, MS, and Elihu Estey, MD

  Abstract: Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in […]

Highlights in Breast Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

Commentary by Hope S. Rugo, MD

  June 2-6, 2017 • Chicago, Illinois Subset of Patients With Heavily Pretreated Metastatic TNBC Respond to Pembrolizumab A subset of patients with heavily pretreated metastatic triple-negative […]

Recent Insights Into the Use of Combination Immunotherapy in Solid Tumors

Jason J. Luke, MD

  H&O  What are the main targets of immunotherapy? JL  In solid tumors, immunotherapy currently focuses the most on the checkpoint proteins cytotoxic T-lymphocyte–associated protein 4 […]

Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer?

Heather Wakelee, MD

  H&O  What is the gold standard method for detecting genetic mutations in patients with lung cancer? HW  The gold standard for detecting genetic mutations remains […]

The Role of D-dimer Testing in Clinical Hematology and Oncology

Charles S. Greenberg, MD

  H&O  What is D dimer? CG  D dimer is a specific antigen derived from the degradation of factor XIIIa cross-linked fibrin. Monoclonal antibodies specific for […]

Letter From the Editor: Take Back the Research

Brad S. Kahl, MD

If you do not read the Editor’s Corner by Mikkael Sekeres in ASH Clinical News, you should. It is a good read. Mikkael’s piece in the […]

Back to Archive